These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8737104)

  • 1. Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands.
    Michel BC; Al MJ; Remme WJ; Kingma JH; Kragten JA; van Nieuwenhuizen R; van Hout BA
    Eur Heart J; 1996 May; 17(5):731-40. PubMed ID: 8737104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost effectiveness of captopril after myocardial infarct; comment].
    Szucs T; Berger K; Schulte-Hillen J; Kleber FX
    Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic aspects of treatment with captopril after MI.
    Davie AP; McMurray JJ
    Eur Heart J; 1996 May; 17(5):648-50. PubMed ID: 8737090
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
    Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases.
    Kleber FX
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):112S-116S. PubMed ID: 7818836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure.
    Szucs TD
    Am J Hypertens; 1997 Oct; 10(10 Pt 2):272S-279S. PubMed ID: 9366284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
    N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.
    Plosker GL; McTavish D
    Drugs Aging; 1995 Sep; 7(3):226-53. PubMed ID: 8535052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure.
    Dasbach EJ; Rich MW; Segal R; Gerth WC; Carides GW; Cook JR; Murray JF; Snavely DB; Pitt B
    Cardiology; 1999; 91(3):189-94. PubMed ID: 10516413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
    Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
    Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
    Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
    Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Captopril in the management of patients after acute myocardial infarctions. A cost effectiveness analysis in Italy.
    Mantovani LG; Belisari A; Szucs TD
    Pharmacol Res; 1998 May; 37(5):345-51. PubMed ID: 9642029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
    Anavekar NS; McMurray JJ; Velazquez EJ; Solomon SD; Kober L; Rouleau JL; White HD; Nordlander R; Maggioni A; Dickstein K; Zelenkofske S; Leimberger JD; Califf RM; Pfeffer MA
    N Engl J Med; 2004 Sep; 351(13):1285-95. PubMed ID: 15385655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness analysis of captopril treatment after myocardial infarction].
    Le Pen C; Lévy E; Bonte J
    Arch Mal Coeur Vaiss; 1994 Jun; 87(6):775-81. PubMed ID: 7702421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction.
    Mason J; Young P; Freemantle N; Hobbs R
    BMJ; 2000 Nov; 321(7269):1113-6. PubMed ID: 11061732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.